Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for CMV Prophylaxis in Heart and Lung Transplant Recipients
NCT06066957Phase 2Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of letermovir in cytomegalovirus infection (CMV), sponsored by University of Pennsylvania. Started Apr 2024; status: active, not recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06066957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066957.